Dr. Zheng Huang is an Associate Professor at the School of Pharmacy and the International Research Institute for Targeted Medicine, Chongqing University of Arts and Sciences. He specializes in the development of multifunctional nanomedicines for the treatment of cancers, focusing particularly on bioenergetic modulation and targeted delivery mechanisms. His work integrates the principles of chemical biology and pharmaceutical nanotechnology to address critical challenges such as multidrug resistance. With a research trajectory that includes a strong foundation in chemistry, advanced training in chemical biology, and academic positions that have steadily progressed from lecturer to associate professor, Dr. Huang has emerged as a prominent young scientist in the field of precision medicine. His innovative research has led to several peer-reviewed publications and a granted patent in China. In addition to being a principal investigator of a competitively funded project supported by the Chongqing Science and Technology Bureau, he actively contributes to the design and synthesis of mitochondria-targeted therapeutics. His efforts have significantly advanced cancer therapy research through novel nanoplatforms and drug delivery mechanisms. With a clear commitment to academic excellence and impactful research, Zheng Huang is a notable contributor to pharmaceutical sciences and biomedical engineering.

Professional Profile

• Scopus Profile

Education

Dr. Zheng Huang pursued his academic training at Sichuan University, one of China’s top-tier research institutions. He completed his Bachelor of Science degree in Chemistry in 2013, where he gained a solid grounding in chemical principles and laboratory techniques. Building upon this foundation, he enrolled in a doctoral program in Chemical Biology at the same university and successfully earned his Ph.D. in June 2018. During his doctoral studies, Dr. Huang engaged in multidisciplinary research that bridged chemistry, biology, and medical applications, setting the stage for his future career in pharmaceutical nanotechnology. His academic training emphasized the synthesis of bioactive compounds, structure-activity relationship studies, and the development of drug delivery systems. This comprehensive education allowed him to develop the theoretical understanding and practical expertise required for innovative research in targeted therapy. The combination of a rigorous undergraduate curriculum and a research-intensive doctoral program equipped him with the skills and knowledge to tackle complex biomedical challenges. Dr. Huang’s academic background continues to influence his current research, providing a strong theoretical and experimental basis for his work on novel drug delivery platforms and cancer therapies. His educational journey has been pivotal in shaping his contributions to biomedical research.

Professional Experience

Dr. Zheng Huang has cultivated a progressive academic career at Chongqing University of Arts and Sciences, particularly within the School of Pharmacy and the International Research Institute for Targeted Medicine. He began his tenure as a Lecturer in July 2018, focusing on pharmaceutical sciences and targeted drug delivery. His appointment was extended from July 2019 to December 2023, reflecting his consistent contributions to teaching and research. In January 2024, he was promoted to the rank of Associate Professor, signifying recognition of his academic achievements and growing leadership in research. Concurrently, he has been a Postdoctoral Fellow at the Chongqing Academy of Chinese Materia Medica since November 2021, further advancing his research in traditional and modern drug systems. Across these roles, Dr. Huang has taken a proactive role in designing and executing research projects, mentoring students, and publishing influential studies. His positions reflect a consistent upward trajectory grounded in scientific rigor and academic service. His interdisciplinary affiliations have enabled him to explore advanced materials, nanotherapeutics, and drug delivery innovations. With dual roles in academia and postdoctoral research, Dr. Huang continues to bridge theoretical advancement and real-world applications, contributing meaningfully to both pharmaceutical education and translational medicine.

Research Interests

Dr. Zheng Huang’s research interests lie at the intersection of nanomedicine, targeted drug delivery, and cancer bioenergetics. He is particularly focused on the design and synthesis of multifunctional nanoplatforms capable of precisely delivering therapeutics to mitochondria within cancer cells. His investigations aim to reverse multidrug resistance through bioenergetic manipulation and redox-responsive systems. Leveraging chemical biology principles, Dr. Huang designs smart drug delivery systems that can respond to the unique microenvironment of tumors, such as elevated reactive oxygen species (ROS) levels or pH changes. His recent work includes developing CPI-613-loaded nanocarriers and co-delivery systems for chemo-photodynamic therapies. These approaches aim not only to enhance drug efficacy but also to minimize off-target toxicity and reduce side effects. Moreover, his work on combining glutathione inhibitors with mitochondria-targeted agents has opened new avenues in photodynamic therapy. Dr. Huang’s interest in structure–activity relationships, gene vectors, and non-viral delivery mechanisms also contributes to the broader field of precision medicine. His research is highly translational, addressing urgent clinical problems while innovating at the molecular level. With an emphasis on therapeutic efficiency and safety, Dr. Huang continues to explore advanced strategies for improving treatment outcomes in breast, pancreatic, and other aggressive cancers.

Research Skills

Dr. Zheng Huang possesses a comprehensive set of research skills that span synthetic chemistry, nanomaterials engineering, and biomedical application development. He is proficient in designing mitochondria-targeted drug delivery systems, with demonstrated success in creating ROS-responsive and bioenergetically active nanocarriers. His expertise includes the fabrication and characterization of nanoparticles, liposomes, and bolasomes for use in cancer therapies. Dr. Huang has strong capabilities in cell culture, fluorescence imaging, cytotoxicity assays, and mitochondrial function analysis, enabling him to evaluate the therapeutic effects of his delivery systems in vitro and in vivo. His proficiency in techniques such as dynamic light scattering (DLS), transmission electron microscopy (TEM), and UV-Vis spectroscopy allows for the precise evaluation of nanostructures and drug release kinetics. Additionally, his understanding of structure–activity relationships informs his rational design of drug molecules and carriers. Dr. Huang is experienced in drafting patents, writing scientific articles, and managing funded research projects, including grant applications and experimental design. His skill set bridges theory and practice, making him well-equipped to develop next-generation nanomedicines. By integrating chemical synthesis with biological evaluation, Dr. Huang continues to contribute meaningfully to the advancement of targeted cancer therapy technologies.

Awards and Honors

While Dr. Zheng Huang has not yet received national academic awards or fellowships, his accomplishments reflect emerging leadership in pharmaceutical nanotechnology. One of his significant achievements includes being the Principal Investigator of a competitively funded research project supported by the Chongqing Science and Technology Bureau under the Chongqing Talent Program. This three-year project, titled “Construction of a multifunctional nanodrug delivery system with controllable energy metabolism for reversing multidrug resistance,” received 100,000 RMB and is currently ongoing from October 2023 to September 2026. In addition, Dr. Huang has successfully secured a Chinese national patent (ZL202110912678.7) for a mitochondria-targeted drug based on CPI-613, highlighting his innovation in targeted cancer therapy. His authorship roles in multiple high-impact journal publications as both sole first author and sole corresponding author further signify his independent research strength and thought leadership. Although national or international honors are yet to be received, the quality and relevance of his contributions suggest strong potential for future recognition. His dedication to solving real-world medical problems through scientific innovation makes him a promising candidate for broader academic and professional accolades.

Conclusion

Dr. Zheng Huang exemplifies the qualities of an emerging leader in targeted drug delivery and pharmaceutical nanotechnology. With a rigorous academic background, progressive professional trajectory, and a growing portfolio of high-impact research, he demonstrates strong potential and scientific merit. His work on mitochondria-targeted therapies and ROS-responsive nanoplatforms addresses some of the most pressing challenges in oncology, such as drug resistance and treatment precision. As a principal investigator of a talent-funded project and the holder of a granted national patent, Dr. Huang’s innovative contributions extend from bench to potential clinical applications. While there is room for expanding his international presence and securing national-level funding such as from NSFC, his current achievements place him among the noteworthy young researchers in biomedical sciences. His publications reflect both technical excellence and relevance to critical health issues. With further support and visibility, Dr. Huang is well-positioned to make significant advances in precision medicine. Based on the evaluation of his academic profile, research outputs, and leadership in innovation, Zheng Huang is a highly suitable nominee for the Best Researcher Award, capable of contributing meaningfully to both scientific discovery and therapeutic development.

Publications Top Notes

1. Novel co‑delivery nanomedicine for photodynamic enlarged immunotherapy by cascade immune activation and efficient immunosuppression reversion

• Year: 2024 (published Nov 1, 2024)

• Journal: Bioorganic Chemistry (Volume 153, Article 107978)

• Authors: Yimei Zhang, Shiyi Xiang, Yayi Wu, Can Yang, Zhongzhu Chen, Dianyong Tang, Zheng Huang

2. Multifunctional Novel Nanoplatform for Effective Synergistic Chemo‑Photodynamic Therapy of Breast Cancer by Enhancing DNA Damage and Disruptions of Its Reparation

• Year: 2023

• Journal: Molecules (Basel, Switzerland)

• Authors: Zheng Huang, Tong Xian, Xiangyi Meng, Huaisong Hu, Yimei Zhang 

3. Carrier‑free nanomedicines self‑assembled from palbociclib dimers and Ce6 for enhanced combined chemo‑photodynamic therapy of breast cancer

• Year: 2023 (first published January 9, 2023)

• Journal: RSC Advances

• Authors: Zheng Huang, Huaisong Hu, Tong Xian, Zhigang Xu, Dianyong Tang, Bochu Wang, Yimei Zhang